Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N
VTVT.OQ - vTv Therapeutics Inc
vTv Therapeutics Inc at TD Cowen Healthcare Conference
Mar 03, 2026 / 02:50PM GMT
=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Doc with Doctor Thomas Strack, our Chief Medical Officer, VTV is a late stage biopharmaceutical company focused on metabolic diseases. Our lead program, Kadazaglitin or CADI, is a potential first in class oral adjunctive therapy to insulin for people living with type one diabetes. Today we'll walk you through the opportunity.
Before we begin, please note that today's discussion contains 4 looking statements. A full description of the associated risks can be found in our SEC filings.
All right, let me quickly frame the VTV investment thesis. Our lead asset, cadasaglitin is in phase redevelopment as a potential first oral adjunctive therapy for type 1 diabetes.
Top-line data from our CAT1 trial
Trustpilot
